Skip to main content

Advertisement

Table 2 Summary of results of pharmacological treatment

From: Systematic review of non-surgical treatments for early Dupuytren’s disease

Author (year) treatment Total cohort of DD patients (hands) Number of patients (hands) with early DD Study type Level of evidence (OCEBM) Prospective (P) Retrospective (R) Not stated (N) Outcome measure Results Recurrence Adverse events
Improved No change Deteriorated
Steroids
 Baxter (1952) [30], Intramuscular 11 (16) 1 (2) Case study 5 (N) Clinical observation of nodules, extension deficit 0 1 0 Not reported Not reported
 Oral 1 (2) Case study 5 (N) Clinical observation of palmar fascia 0 1 0 Not reported Not reported
 Ketchum (2000) [31], Injection 63 (75) 63 (75) Case series 4 (N) Nodule easier to inject and flatter 62 patients (73 hands) 0 1 patient (2 hands) 50 % of patients at 1 to 3 years 50 % patients reported transient depigmentation or temporary subcutaneous atrophy at injection site. ‘Nearly all’ resolved at 6 months
Clinically observed digital contracture 0 62 patients (73 hands) 1 patient (2 hands)
 Shelley (1993) [32], Topical 2 1 Case study 5 (N) Contracture shrinkage 1 0 0 None at 2 years Not reported
 Zachariae (1955) [33], Injection 11 (11) 9 (9) Case series 4 (N) Fibrosis diminished or softer 9 0 0 1 at 14 months Not reported
 Coste (1953) [34], Injection 9 (13) 2 (2) Case series 4 (N) Clinical observation of nodules, extension deficit 2 0 0 Not reported Not reported
Vitamin E (oral)
 Reilly (1974) [35] 1 (2 hands) 1 (2 hands) Case study 5 (N) Clinical observation 0 0 1 patient (2 hands) Eventually required surgery in both hands Not reported
 Richards (1952) [36] 70 hands 63 hands Case series 4 (N) Observation, deformity monitored using plaster cast moulds 0 60 3 Not reported No toxic effects
 Steinberg (1951) [18] 22 6 Case series 4 (N) Clinical observation 6 0 0 Not reported Not reported
Other
 Skliarenko (1982) [37], furazolidone injection 98 74 Case series 4 (N) Clinically observed digital contracture 74 0 0 9 patients in total cohort (4 at 1 year, 3 at 2 years, 2 after 3 years) 18 of total cohort of 98 reported minor hand swelling, raised temperature after 1st injection. No systemic side effects.
 Gatev (1997) [38], Topical aminosyn and ultrasound 63 22 Cohort study 4 (N) Clinical observation of palm thickening, tension and trembling 21 1 0 Not reported Not reported
 Topical aminosyn 4 4 0 0
 Ultrasound 6 4 2 0
 Yildiz (2004) [39], Hyperbaric oxygen 1 1 Case study 5 (N) Extension deficit, clinical observation 1 0 0 None at 1 year No adverse effects.
  1. Summary of results of pharmacological treatment from each study, including the number of patients with Dupuytren’s disease in the total cohort in each study, the number of patients with early disease within the total cohort, study type and design, level of evidence according to the Oxford Centre for Evidence Based Medicine (OCEBM) criteria, the outcome measure used and results. The number of hands (in brackets) is stated when available, with recurrence and adverse events where stated